Meronex

Meronex is a broad-spectrum carbapenem antibiotic indicated for the treatment of severe and life-threatening infections caused by multidrug-resistant Gram-positive and Gram-negative bacteria.
It offers rapid bactericidal action, exceptional tissue penetration, and excellent tolerance, making it a trusted choice in critical and hospital-acquired infections.

• Broad-Spectrum Power – Effective against resistant Gram– and Gram+ bacteria
• Rapid Action – Quick bacterial killing with high efficacy
• Critical Care Grade – Ideal for severe and hospital-acquired infections

• Excellent Safety Profile – Minimal nephrotoxicity and neurotoxicity

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
It is resistant to most β-lactamases and exhibits strong stability against extended-spectrum β-lactamases (ESBLs), making it highly effective for multi-resistant bacterial infections.

• Broad Coverage: Active against resistant pathogens including Pseudomonas and Acinetobacter.

• Rapid Bactericidal Effect: Ensures quick clinical improvement in severe infections.

• Hospital Grade: Trusted in ICU, surgical, and emergency care settings.

• Safe & Stable: Low cross-allergenicity, minimal renal or CNS adverse effects.

• Lower respiratory tract infections (pneumonia, HAP, VAP)

• Urinary tract infections (complicated & uncomplicated)

• Intra-abdominal infections

• Skin & soft tissue infections

• Meningitis (bacterial)

• Septicemia & febrile neutropenia

• Gynecological infections

• Bone & joint infections

• Adjust dose in renal impairment.

• Use with caution in patients with a history of β-lactam allergy or seizures.

• Administer under medical supervision only.

Generally well-tolerated under medical supervision.
Mild side effects may include nausea, diarrhea, headache, or rash.
Occasionally, injection site inflammation, thrombophlebitis, or elevated liver enzymes may occur.
Rarely, hypersensitivity reactions or seizures may be seen in patients with CNS disorders or renal impairment.

• Adults: 500 mg to 1 g every 8 hours by IV infusion, depending on infection severity.

• Children: Dosage as per body weight and clinical condition.

• Route: Intravenous (IV) injection or infusion only.

• Reconstitution: Dissolve in sterile water for injection or appropriate diluent before use.